MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Account Payables
Amounts the company owes suppliers for goods and services received.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Account Payables · Q3 FY2026 · quarter ended Sep 2026
Account payables rises 80.6% from a year ago
Account payables stood at $6.81M at the end of Q3 FY2026, up 80.6% from a year earlier and up 56.2% from the prior quarter. Over 3 fiscal years it compounded at +45.0% a year.
Context
- Account payables amounted to 1.4% of total assets at the end of Q3 FY2026, up 0.4 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +80.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.98M USD
- Year-over-year change
- -44.2%
- 3-year CAGR
- +45.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.98M | -44.2% |
| FY2024 | 2024-12-31 | 5.34M | +283.5% |
| FY2023 | 2023-12-31 | 1.39M | +42.5% |
| FY2022 | 2022-12-31 | 976K | — |
Account Payables vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +80.6% is the 2nd highest of 8, against a peer median of +39.6%.
- Account payables amounts to 1.4% of total assets for MBX, versus a peer median of 2.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €109.72M EUR | +39.6% | -3.6% | 4.5% | |
| Jun 2026 | $69.01M USD | +1156.1% | +84.1% | 13.2% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $19.2M USD | — | — | 1.6% |
| Mar 2026 | $11.47M USD | +80.5% | -12.6% | 2.9% | |
| Sep 2026 | $10.69M USD | -21.6% | +42.7% | 2.4% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $6.81M USD | +80.6% | +45.0% | 1.4% |
| Mar 2026 | $4.61M USD | -40.1% | -22.1% | 9.9% | |
| Mar 2026 | $1.53M USD | +42.1% | -17.3% | 0.5% | |
| Mar 2026 | $481K USD | -5.5% | -41.2% | 0.2% | |
| Peer median (excluding MBX) | — | +39.6% | -12.6% | 2.7% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.